Madrigal Pharmaceuticals (MDGL) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Madrigal Pharmaceuticals (MDGL) overview

Madrigal Pharmaceuticals (MDGL) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 958m and operating profit of USD -300m; the year-end share price was 582.34 USD and market capitalisation was USD 13,302m. Madrigal Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Madrigal Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 603mFY 2025
Share price582.34 USDFY 2025 year end
RevenueUSD 958mFY 2025
Operating profitUSD -300mFY 2025
Net earningsUSD -288mFY 2025
Market capitalisationUSD 13,302mFY 2025 year end

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals develops therapeutics for metabolic dysfunction-associated steatohepatitis, a liver disease. Its medicine Rezdiffra is an oral, liver-directed therapy approved for adults with noncirrhotic disease and moderate to advanced liver fibrosis. The company markets Rezdiffra in the United States and Germany and is developing additional drug candidates, including oral agents and small interfering RNA programs, for MASH.

Generate the Madrigal Pharmaceuticals report

Madrigal Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Madrigal Pharmaceuticals and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Madrigal Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.